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MaOBJECTIVES This study sought to assess the frequency and clinical impact of dual antiplatelet therapy (DAPT)
nonadherence.
BACKGROUND There are limited data on the impact of DAPT nonadherence during the ﬁrst year after a
second-generation drug-eluting stent placement.
METHODS After successful Endeavor zotarolimus-eluting stent implantation, 2,265 patients were enrolled in a registry
with limited exclusions and monitored during 12 months of prescribed DAPT. Predictors of any nonadherence (ANA) at
6 months were analyzed by multivariable analysis, and the association between ANA at 6 or 12 months with the endpoints
of death, myocardial infarction, and stent thrombosis was assessed.
RESULTS The study population included 30% female patients, 34% with diabetes and 36% with acute coronary
syndromes. ANA occurred in 208 patients (9.6%) before 6 months and 378 patients (18.5%) before 1 year. Major
bleeding (odds ratio [OR]: 12.83, 95% conﬁdence interval [CI]: 7.55 to 21.80, p < 0.001) was the only predictor of ANA
at 6 months. In time-dependent analyses, ANA before 6 months was associated with an increased risk of death or
myocardial infarction (7.6% vs. 3.0%, p < 0.001) and a numerical increase in stent thrombosis (2.0% vs. 0.9%,
p ¼ 0.12). After adjustment for baseline differences, ANA within 6 months remained associated with death or MI
(OR: 1.95, 95% CI: 1.02 to 3.75). ANA occurring after 6 months did not increase the risk of subsequent ischemic events.
CONCLUSIONS DAPT ANA occurs frequently and is associated with increased risk for thrombotic complications
if it occurs within the ﬁrst 6 months. Major bleeding was a signiﬁcant correlate of DAPT ANA within 6 months.
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AB BR E V I A T I O N S
AND ACRONYM S
ANA = any nonadherence
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent
E-ZES = Endeavor
zotarolimus-eluting stent
MI = myocardial infarction
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405W hen used in routine practice, ﬁrst-generation drug-eluting stents (DES)increased the risk for stent thrombosis
beyond the traditional subacute (30-day) period as
compared with the risk associated with bare-metal
stents (1,2). In 2007, the consensus recommendation
from cardiology societies and the U.S. Food and
Drug Administration was for 12 months of continuous
dual antiplatelet therapy (DAPT) (3,4). Despite earlier
concerns that 12 months of continuous DAPT might be
too short, several randomized trials have not
conﬁrmed a beneﬁt for therapy beyond 12 months
(5–7). Due to low event rates and issues of trial design,
a more deﬁnitive assessment of the prolonged DAPT
controversy awaits completion of the larger DAPT
randomized trial (8). Meanwhile, based on lower rates
of late stent thrombosis with newer generation DES,
other studies have tested even shorter DAPT dura-
tions of 3 or 6 months in low-risk populations and
shown no statistical difference compared with the
standard 12-month duration (9–11).SEE PAGE 411Similarly, the signiﬁcance of interruptions or any
nonadherence (ANA) to DAPT during the prescribed
12 months is unclear. Indeed, recent observational
studies have suggested that interruptions as early as
31 days are not associated with increased risk for stent
thrombosis (12–15), but these studies have either not
addressed the speciﬁc impact of ANA at intervals
between 31 days and 6 months, had infrequent ANA
during this interval, or had low overall event rates.
Given this ongoing controversy, we explored the
issue of early (within 6 months) or late (6 to 12
months) DAPT ANA after second-generation DES
placement in the context of a large prospective
multicenter registry. We hypothesized that ANA to
prescribed DAPT within 6 months is associated with
increased risk of thrombotic events; additionally, we
sought to assess the frequency and predictors of
nonadherence within 6 months.
METHODS
PATIENT POPULATION. The EDUCATE (Endeavor
Drug-Eluting Stenting: Understanding Care, Anti-
platelet Agents and Thrombotic Events) registry is a
prospective registry designed to assess practice pat-
terns and patient adherence to DAPT and the risk of
subsequent thrombotic events. All patients >18 years
of age undergoing coronary stenting with an
Endeavor zotarolimus-eluting stent (E-ZES) (Med-
tronic, Minneapolis, Minnesota) of diameter 2.5 to
3.5 mm at a participating institution and with lifeexpectancy >3 years were eligible for partic-
ipation. After 12 months of follow-up, pa-
tients who were free of ischemic or bleeding
events and who met appropriate inclusion
and exclusion criteria were to be randomized
to continue aspirin plus clopidogrel (or pra-
sugrel) or aspirin plus placebo for an addi-
tional 18 months as part of the larger DAPT
trial (8). This report is limited to events in the
ﬁrst 12 months prior to randomization and
includes all subjects enrolled. The study was
approved by the appropriate ethics review committee
for each participating institution.
DUAL ANTIPLATELET THERAPY AND MEDICATION
ADHERENCE. All patients were prescribed open-label
aspirin plus either clopidogrel or prasugrel for a rec-
ommended duration of 12 months. Adherence to
study medication was assessed during follow-up
visits at 30 days, 6 months, and 12 months. The
duration of all interruptions was recorded. ANA was
deﬁned as missing 1 or more days of either medica-
tion. Severe nonadherence was deﬁned as missing 14
or more consecutive days of either study medication.
STUDY ENDPOINTS. Endpoints included all-cause
mortality, cardiac death, myocardial infarction (MI),
stent thrombosis, and major bleeding. A composite
endpoint of death or MI was also analyzed. Cardiac
death included all deaths for which a cardiac cause
could not be excluded. MI was deﬁned during the
periprocedural period (48 h) as creatine kinase-
myocardial band or troponin >3 the individual
clinical center upper reference limit and during
follow-up based on evidence of ischemic signs or
symptoms and any elevation of troponin or creatine
kinase-myocardial band. Stent thrombosis was
deﬁned according to the Academic Research Con-
sortium classiﬁcation and reported as deﬁnite or
probable (16). Major bleeding events were classiﬁed
according to the GUSTO (Global Use of Strategies to
Open Coronary Arteries) trial as moderate or severe
(17). All endpoints were adjudicated by an indepen-
dent clinical events committee.
STATISTICAL ANALYSIS. Primary comparisons for
this analysis are between subjects with ANA and
those with full adherence to prescribed DAPT during
the ﬁrst 6 months after stent implantation. Categori-
cal data are reported as percentages and compared
using chi square. Continuous variables are reported
as mean  SD and compared using a Student t test.
The cumulative incidence of ANA, severe non-
adherence, and clinical endpoints were calculated
using the Kaplan-Meier method, and differences in
clinical outcomes between groups were compared
TABLE 1 Baseline Clinical Characteristics According to 6-Month
DAPT Adherence
Any
Nonadherence
(n ¼ 208)
Full
Adherence
(n ¼ 1,951) p Value
Age, yrs, mean 65.6 63.8 0.02
Female 34.6 29.8 0.15
Diabetes mellitus 41.3 33.2 0.02
Hypertension 83.2 81.9 0.71
History of smoking 59.6 56.7 0.46
Hyperlipidemia 83.2 83.0 1.00
Previous MI 27.4 23.8 0.27
Previous PCI 38.9 35.7 0.36
Previous heart failure 15.4 8.0 <0.01
PCI for acute coronary
syndrome
52.9 46.5 0.08
Renal insufﬁciency 8.5 6.4 0.28
Previous stroke or TIA 11.1 5.6 <0.01
History of GI bleeding 2.4 0.9 0.06
Previous CABG 16.3 14.9 0.54
Warfarin 5.3 2.4 0.02
Clopidogrel 75.0 76.7 0.60
Prasugrel 18.3 16.9 0.63
Multiple stents 36.5 35.2 0.70
Values are percentages unless otherwise indicated.
CABG ¼ coronary artery bypass graft; GI ¼ gastrointestinal; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic
attack.
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406using the log rank test. Because periprocedural
events are unrelated to DAPT adherence, the time-
dependent analysis began after 48 h. Patients were
analyzed according to the timing of ANA, such that
events occurring in patients with eventual ANA but in
the interval prior to ANA are analyzed as full adher-
ence. The predictors of ANA and independent corre-
lates of the composite of death or MI were assessed
using logistic regression. All statistical analyses were
performed using SAS (version 9.1 or higher, SAS
Institute, Cary, North Carolina).
RESULTS
STUDY POPULATION. Of 2,265 consecutive patients
enrolled, 10 subjects were withdrawn due to admin-
istrative reasons at 1 site and data for DAPT adherence
were missing for 96 subjects. Thus, 2,159 patients
were included in the ﬁnal analysis (Figure 1).
Approximately one-third of patients had diabetes
mellitus and one-third were enrolled after presenta-
tion with an acute coronary syndrome (Table 1).
Compared with patients with full adherence to DAPT,
patients with ANA were slightly older and had higher
frequency of diabetes, heart failure, previous stroke
or transient ischemic attack, peripheral vascular dis-
ease, and warfarin use.
FREQUENCY AND PREDICTORS OF DAPT NON-
ADHERENCE. The cumulative incidence of DAPT
nonadherence is shown in Figure 2. By 6 months, 208
patients (9.6%) reported ANA, including severe non-
adherence in 112 (5.2%). The only signiﬁcantEnrollment
2265 Patients enrolled 
ts
 at 6 mo  
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     96 Missing data   
1951 Patients
Full adherence at 6 mo  
170 Patients
Any nonadherence
at 6-12  mo    
1881 Patients 
Full adherence 
at 12 mo
ow chart depicting frequency of any nonadherence at 6 months and
dherence after 6 months.independent correlate with ANA during the ﬁrst
6 months was the development of a major bleeding
event (odds ratio: 12.83, 95% conﬁdence interval: 7.55
to 21.80, p < 0.001). Requirement for noncardiac
surgery was not a signiﬁcant predictor of ANA. Of
note, however, only 23 patients underwent noncar-
diac surgery or an invasive procedure within
6 months.
CLINICAL OUTCOMES AND DAPT NONADHERENCE.
One-year unadjusted clinical outcomes based on
6-month DAPT adherence are shown in Table 2 and
Figure 3. Individual endpoints of all-cause mortality,
cardiac death, MI, and stent thrombosis as well as the
composite endpoint of death or MI were all more
frequent for ANA within 6 months of DES implanta-
tion. After adjustment for differences in baseline
characteristics, ANA within 6 months remained a
signiﬁcant correlate of death or MI (Table 3). The risk
for the composite endpoint of death or MI was similar
for ANA between 0 to 90 days and 91 to 180 days
(8.9% vs. 7.0%). In contrast, for patients who were
fully adherent to DAPT during the ﬁrst 6 months,
subsequent nonadherence after 6 months compared
with continued full adherence was not associated
with increased subsequent risk for the composite
endpoint of death or MI (1.1% vs 1.3%).
FIGURE 2 Cumulative Incidence of Nonadherence to Prescribed DAPT
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Cumulative incidence of any nonadherence and severe nonadherence during the 12 months of prescribed therapy. DAPT ¼ dual antiplatelet
therapy.
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407Major bleeding was more frequent in the early ANA
group (Figure 3C), with most bleeding occurring
within the ﬁrst 6 months and preceding non-
adherence in all cases. The risk for death or MI was
signiﬁcantly higher among the 22 patients with ANA
that was associated with major bleeding than for
other ANA (35.0% vs. 7.0%, p < 0.001).
DISCUSSION
In this broadly inclusive multicenter international
registry of patients undergoing stenting with the
E-ZES, nonadherence with the prescribed 12 monthsTABLE 2 1-Year Clinical Outcomes According to 6-Month
DAPT Adherence
Any
Nonadherence
(n ¼ 208)
Full
Adherence
(n ¼ 1,951) p Value
All-cause mortality 5.0 1.7 0.001
Cardiac death 2.5 0.9 0.028
MI 4.7 1.5 0.002
Death or MI 7.6 3.0 <0.001
Deﬁnite or probable ST 2.0 0.9 0.123
Major bleeding 16.2 2.7 <0.001
Stroke 3.5 0.6 <0.001
Values are percentages.
DAPT ¼ dual antiplatelet therapy; MI ¼ myocardial infarction; ST ¼ stent
thrombosis.of DAPT was frequent, including prolonged (>14 days)
nonadherence in over 5% of patients within 6 months
of DES implantation. ANA in the ﬁrst 6 months
correlated strongly with the occurrence of major
bleeding. ANA within the ﬁrst 6 months was inde-
pendently associated with adverse thrombotic out-
comes at 1 year. For patients fully compliant with
DAPT during the ﬁrst 6 months after E-ZES implan-
tation, subsequent ANA between 6 and 12 months did
not confer increased ischemic risk.
Our ﬁndings contribute signiﬁcantly to the ongoing
debate regarding the timing and risk of DAPT inter-
ruption after second-generation DES implantation.
Although the concept of DAPT duration as short as
3 months after E-ZES as suggested by Kim et al. (10) is
attractive, our ﬁndings raise concern about broad
application of this practice. Similarly other studies
assessing DAPT durations shorter than 12 months may
have limited statistical power to assess differences in
stent thrombosis and may not be generalizable to
higher-risk routine practice populations (6,9,11).
Moreover, our ﬁndings suggest that clinical atten-
tion to the problem of DAPT nonadherence remains
important for the ﬁrst 6 months after second-
generation DES implantation. There is general
agreement with this concern within the ﬁrst 30 days
after DES implantation (13,15,18,19), but our data are
in contrast to several studies reporting no adverse
impact of DAPT interruptions after 30 days (13,15,20).
FIGURE 3 Cumulative Incidences of Clinical Outcomes
A
B
(A) Cumulative incidence of death or myocardial infarction for any nonadherence within 6 months compared with full adherence for 6 months.
(B) Cumulative incidence of stent thrombosis for any nonadherence within 6 months compared with full adherence for 6 months.
(C) Cumulative incidence of major bleeding for any nonadherence within 6 months compared with full adherence for 6 months.
Continued on the next page
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with DAPT interruptions between 30 days and 1 year
and, compared with patients without interruptions,
noted no increase in major adverse cardiac events.
These investigators grouped all interruptions be-
tween 30 days and 1 year, however, and interruptions
in the ﬁrst 6 months were infrequent. Similarly,
Silber et al. (15) reported that ANA between 30 days
and 1 year after implantation of the Resolute ZES
was not associated with an increased risk for
cardiac death or MI, but also did not distinguishnonadherence before or after 6 months. Naidu et al.
(13) also did not note an increased risk for 1-year stent
thrombosis with interruptions after 30 days in the
XIENCE V USA (XIENCE V Everolimus Eluting Coro-
nary Stent System USA post-approval study), but the
rate of stent thrombosis was very low (0.8%) and
the effect of interruptions before 6 months was not
reported.
Previous studies have suggested that re-
endothelialization after ﬁrst- or second-generation
DES may continue well beyond 30 days, especially
FIGURE 3 Continued
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409when used for longer and more complex lesions
(21–24). Thus we hypothesized that DAPT in-
terruptions were more likely to be associated with
thrombotic events during the entire period of early
healing. Our ﬁndings that full adherence to DAPT is
most important in the ﬁrst 6 months are consistent
with those of a large Japanese registry by Kimura
et al. (12), which demonstrated no clinical beneﬁt
for continued thienopyridine in addition to aspirin
beyond 6 months after sirolimus-eluting stent place-
ment. Our results extend these ﬁndings to the
second-generation E-ZES stent used in patients seen
during routine practice in the United States.
Recently, Mehran et al. (14) reported that DAPT
interruptions during the ﬁrst 2 years after DES im-
plantation had a variable effect on clinical outcome
depending on the reason for interruption. They noted
that therapy “disruptions” due to major bleeding, but
not physician-directed interruptions due to a need
for noncardiac surgery, were associated with an
increased risk for major adverse cardiac events. In
their study, DAPT disruption occurred at a mean ofTABLE 3 Predictors of 1-Year Death or MI
Odds Ratio (95% CI) p Value
Any nonadherence at 6 months 1.95 (1.02–3.75) 0.045
Diabetes 3.16 (1.89–5.27) <0.001
Age, per year 1.06 (1.03–1.09) <0.001
Current smoking 2.83 (1.57–5.08) <0.001
Nonelective procedure 2.04 (1.22–3.45) 0.006
Other variables that were included in the multivariable regression model and were
not signiﬁcant included: previous MI, previous CABG, previous PCI, previous stroke
or TIA, history of heart failure, and history of peripheral vascular disease.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.230 days after stenting and frequently involved
stopping both aspirin and a thienopyridine, whereas
other interruptions occurred at mean 357 days and
aspirin was usually continued. Our multicenter reg-
istry ampliﬁes these ﬁndings by identifying an inde-
pendent association of major bleeding with ANA
within 6 months, and consistent with Mehran et al.
(14), conﬁrming these clinically triggered inter-
ruptions were associated with a signiﬁcant risk of
ischemic events. Our ﬁndings emphasize that this
association is only true if the interruption occurred
within 6 months of DES implantation. The failure to
reliably predict nonadherence in most cases points to
the difﬁculty in preventing these events.
STUDY LIMITATIONS. Our study is a multicenter
prospective registry and not a randomized clinical
trial. Patients with ANA are different than those
without ANA. We used multivariable analysis to
control for differences between ANA and fully
adherent patients, but it is possible that unknown
confounders may lead to increased risk of ischemic
events associated with DAPT nonadherence. Our
study identiﬁed major bleeding as the sole indepen-
dent predictor of ANA. It is possible that other lower
frequency events (i.e., noncardiac surgery after DES
implantation) might be associated with ANA and a
larger registry would be required to determine this
deﬁnitively. Finally, our study analyzed the impact of
early ANA versus late ANA with respect to 1 second-
generation DES (E-ZES), which is no longer in gen-
eral use. Although this DES has been associated with
low risk of late stent thrombosis, the applicability of
our ﬁndings to other DES with possible lower risk for
stent thrombosis warrants further study.
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newer generation DES is uncertain. Given reports of
lower late stent thrombosis for both the cobalt chro-
mium everolimus-eluting stent and the Resolute ZES,
there has been increased interest in even shorter
durations of prescribed DAPT (25). Importantly, the
E-ZES used in our study has also been associated with
lower risk for very late stent thrombosis (26).
CONCLUSIONS
Any nonadherence to DAPT occurred frequently and
was associated with increased risk for death or
myocardial infarction if within the ﬁrst 6 months.Our results suggest that larger randomized clinical
trials including higher-risk patients treated in
routine practice are required to determine the
safety of durations of uninterrupted DAPT therapy
<6 months.
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